Alterity Therapeutics (Alterity Therapeutics) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics 3-Year Dividend Growth Rate?

Alterity Therapeutics's Dividends per Share for the three months ended in Sep. 2023 was $0.00.

The historical rank and industry rank for Alterity Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

ATHE's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Alterity Therapeutics's Dividend Payout Ratio for the three months ended in Sep. 2023 was 0.00. As of today, Alterity Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Alterity Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Alterity Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's 3-Year Dividend Growth Rate falls into.

Alterity Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Alterity Therapeutics (NAS:ATHE) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Alterity Therapeutics's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	0
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics 3-Year Dividend Growth Rate Related Terms>

Alterity Therapeutics (Alterity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

PBN:Germany ATH:Australia

Address

350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000

Website

https://www.alteritytherapeutics.com

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.